Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Osteoporosis 1Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × Raloxifene Hydrochloride × Clear all
NCT04926545 2024-07-30

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Guangzhou University of Traditional Chinese Medicine

Phase NA Completed
24 enrolled

Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡